This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 May 2012

Pharmaceuticals Industry Sees Spate of M&A Activity

Some $33 billion of M&A activity took place among pharmaceuticals companies in April.

Mergers and acquisitions (M&A) to the tune of $33 billion (£20.4 billion) took place among pharmaceuticals companies last month, making healthcare the busiest sector for this kind of activity in April.


Figures from tracker Dealogic, provided to the Financial Times, highlight AstraZeneca's $1.3 billion purchase of Ardea as one of the major completed transactions.


GlaxoSmithKline, meanwhile, is currently involved in a $2.6 billion takeover for Human Genome Science, which is involved in the development of Benlysta for lubus.


Rick Leaman, of investment bank Moelis & Co, told the news provider that big pharmaceuticals companies are currently attracted to mergers and acquisitions as a way of

Related News